{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:08:52Z","timestamp":1789189732538,"version":"build-2803163510"},"reference-count":17,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.26-0383","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:15:04Z","timestamp":1788992104000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Combining Pembrolizumab and Ofatumumab in Triple-Negative Breast Cancer and Multiple Sclerosis: A Case Report"],"prefix":"10.70352","volume":"12","author":[{"given":"Haruna","family":"Iriyama","sequence":"first","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Iwase","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ohata","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gai","family":"Inaguma","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Torii","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kawabe","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyone","family":"Kikumori","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan"},{"name":"Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","unstructured":"1) Kabushiki Gaisha MSD. Triple negative breast cancer: product characteristics (in Japanese). MSD connect. 2025. https:\/\/www.msdconnect.jp\/products\/keytruda-tnbc\/characteristic\/. Accessed 30 Mar 2025."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382: 810\u201321.","DOI":"10.1056\/NEJMoa1910549"},{"key":"3","unstructured":"3) Japanese Society of Neurology. Clinical practice guidelines for multiple sclerosis and neuromyelitis optica spectrum disorder 2023 (in Japanese). https:\/\/www.neurology-jp.org\/guidelinem\/pdf\/koukasyo_nmosd_2023.pdf. Accessed 30 Jan 2026."},{"key":"4","unstructured":"4) Ministry of Health, Labour and Welfare, Research Group on Intractable Diseases. Multiple sclerosis\/neuromyelitis optica (Designated intractable disease No.13) (in Japanese). Nanbyo Joho Center. 2023. https:\/\/www.nanbyou.or.jp\/entry\/3806. Accessed 30 Mar 2025."},{"key":"5","unstructured":"5) Novartis Pharma Kabushiki Gaisha. Kesimpta. Novartis Pharma professional site (in Japanese). 2025. https:\/\/www.pro.novartis.com\/jp-ja\/products\/kesimpta. Accessed 30 Mar 2025."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Fletcher K, Machaalani M, El Hajj Chehade R, et al. Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders. JAMA Netw Open 2025; 8: e2513727.","DOI":"10.1001\/jamanetworkopen.2025.13727"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Hirunpattarasilp C, Fu P, Margevicius SP, et al. Outcomes in patients with multiple sclerosis and solid organ cancers treated with immune checkpoint inhibitors. Neurooncol Adv 2025; 7: vdaf048.","DOI":"10.1093\/noajnl\/vdaf048"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Gelibter S, Saraceno L, Susani E, et al. Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis. Eur J Neurol 2025; 32: e16547.","DOI":"10.1111\/ene.16547"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Afzal S, Li Y, Lapin B, et al. Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors. Ann Clin Transl Neurol 2025; 12: 643\u20137.","DOI":"10.1002\/acn3.52287"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Garcia CR, Jayswal R, Adams V, et al. Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol 2019; 21: 1336\u201342.","DOI":"10.1007\/s12094-019-02060-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Conway SE, Galetta K. Therapeutic advances in multiple sclerosis: novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L). Neurotherapeutics 2025; 22: e00558.","DOI":"10.1016\/j.neurot.2025.e00558"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nylander AN, Rowles W, Poole S, et al. Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis. Mult Scler J Exp Transl Clin 2024; 10: 20552173241252563.","DOI":"10.1177\/20552173241252563"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Neuzil K, Gessner K, Hedgepeth J, et al. Complete pathologic response to pembrolizumab and axitinib in a patient with sarcomatoid RCC and ocrelizumab-treated multiple sclerosis. Urology 2022; 164: 50\u20134.","DOI":"10.1016\/j.urology.2021.12.015"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Isitan C, Wesley S. Safety of checkpoint inhibitors for cancer treatment in patients with multiple sclerosis: a case report (P1.7-006). Neurology 2019; 92: 1.7-006.","DOI":"10.1212\/WNL.92.15_supplement.P1.7-006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lu BY, Isitan C, Mahajan A, et al. Intracranial complications from immune checkpoint therapy in a patient with NSCLC and multiple sclerosis: case report. JTO Clin Res Rep 2021; 2: 100183.","DOI":"10.1016\/j.jtocrr.2021.100183"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Gettings EJ, Hackett CT, Scott TF. Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler 2015; 21: 670.","DOI":"10.1177\/1352458514549403"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Iglesias Martinez B, Insa A, Cervera Ygual G, et al. Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis. Lung Cancer 2025; 202: 108464.","DOI":"10.1016\/j.lungcan.2025.108464"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0383\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:04:37Z","timestamp":1789189477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.26-0383\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.26-0383","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.26-0383"}}